Microbix Biosystems (TSE:MBX) Issues Earnings Results

Microbix Biosystems (TSE:MBX) posted its earnings results on Thursday. The company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of C$4.06 million for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.

Here are the key takeaways from Microbix Biosystems’ conference call:

• Positive Sentiment: Q3 revenue increased 17% year over year, with antigen sales up 20% and QAP sales up 13%. Management expects continued year-over-year and sequential growth in Q4, moving closer to break-even.
• Positive Sentiment: Gross margin improved to 54% from 41% a year earlier, aided by product mix, manufacturing efficiencies, higher yields, and better fixed-cost absorption.
• Positive Sentiment: Kinlytic development is progressing toward an FDA meeting on comparability protocols before year-end and an anticipated supplemental BLA filing in 2027. Process improvements have increased drug-substance yields and could improve future margins.
• Positive Sentiment: Microbix is pursuing several potentially material QAP projects with major international diagnostics companies, including synthetic controls for RNA-based viruses and products for assays on large installed instrument bases. Management expects initial customer-related disclosures during the balance of calendar 2026, although timing remains client-controlled.
• Negative Sentiment: The company remains a net user of cash and reported a quarterly net loss of approximately CAD 800,000, despite holding CAD 7.2 million in cash. Management is balancing share buybacks with preserving liquidity for potential production expansion and limiting the need for future equity financing.

Microbix Biosystems Trading Down 9.4%

Shares of MBX stock traded down C$0.03 on Thursday, hitting C$0.29. The stock had a trading volume of 96,421 shares, compared to its average volume of 51,354. The firm has a market cap of C$39.88 million, a P/E ratio of -7.07 and a beta of 0.72. Microbix Biosystems has a twelve month low of C$0.21 and a twelve month high of C$0.32. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The company has a fifty day moving average price of C$0.30 and a two-hundred day moving average price of C$0.26.

Insider Transactions at Microbix Biosystems

In other Microbix Biosystems news, Director Martin Marino purchased 115,000 shares of the stock in a transaction on Thursday, May 28th. The stock was bought at an average cost of C$0.28 per share, for a total transaction of C$32,200.00. Following the completion of the acquisition, the director directly owned 2,000,167 shares of the company’s stock, valued at C$560,046.76. The trade was a 6.10% increase in their ownership of the stock. Insiders bought 251,000 shares of company stock valued at $68,355 over the last ninety days. 14.00% of the stock is currently owned by insiders.

Microbix Biosystems Company Profile

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.